Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
04
05
2020
accepted:
27
10
2020
revised:
26
10
2020
pubmed:
19
11
2020
medline:
24
6
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
ASP4345, a novel dopamine D
Identifiants
pubmed: 33203954
doi: 10.1038/s41386-020-00908-0
pii: 10.1038/s41386-020-00908-0
pmc: PMC8182805
doi:
Substances chimiques
Receptors, Dopamine
0
Dopamine
VTD58H1Z2X
Banques de données
ClinicalTrials.gov
['NCT02720263']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1145-1151Références
Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205:929–32.
doi: 10.1126/science.112679
Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010;68:815–34.
doi: 10.1016/j.neuron.2010.11.022
Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci. 2007;30:259–88.
doi: 10.1146/annurev.neuro.28.061604.135722
Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology. 2004;174:3–16.
doi: 10.1007/s00213-004-1793-y
Arnsten AF, Girgis RR, Gray DL, Mailman RB. Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry. 2017;81:67–77.
doi: 10.1016/j.biopsych.2015.12.028
Ott T, Nieder A. Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci. 2019;23:213–34.
doi: 10.1016/j.tics.2018.12.006
Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry. 2006;67 Suppl 9:9–13.
pubmed: 16965183
Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, et al. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112. J Psychopharmacol. 2012;26:794–805.
doi: 10.1177/0269881111409265
Hall A, Provins L, Valade A. Novel strategies to activate the dopamine D(1) receptor: recent advances in orthosteric agonism and positive allosteric modulation. J Med Chem. 2019;62:128–40.
doi: 10.1021/acs.jmedchem.8b01767
Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, et al. Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Mol Pharmacol. 2018;94:1197–209.
doi: 10.1124/mol.118.113175
Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson’s disease. Clin Neuropharmacol. 1998;21:339–43.
pubmed: 9844789
Starr MS, Starr BS. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm Park Dis Dement Sect. 1993;6:27–34.
doi: 10.1007/BF02252620
Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, et al. Pharmacokinetics of ASP4345 from single ascending-dose and multiple ascending-dose phase I studies. Clin Pharmacokinet. 2020. https://doi.org/10.1007/s40262-020-00911-0 .
Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016;30:428–35.
doi: 10.1177/0269881116636120
Pietrzak RH, Snyder PJ, Maruff P. Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophr Res. 2010;124:176–82.
doi: 10.1016/j.schres.2010.09.012
Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010;25:353–8.
doi: 10.1002/hup.1118
Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012;71:873–80.
doi: 10.1016/j.biopsych.2012.01.016
Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006;60:1231–40.
doi: 10.1016/j.biopsych.2006.03.055
Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia. Neuropsychopharmacology. 2017;42:2633–9.
doi: 10.1038/npp.2017.81
Rissling AJ, Miyakoshi M, Sugar CA, Braff DL, Makeig S, Light GA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. NeuroImage Clin. 2014;6:424–37.
doi: 10.1016/j.nicl.2014.09.006
Seech TR, Funke ME, Sharp RF, Light GA, Blacker KJ. Impaired sensory processing during low-oxygen exposure: a noninvasive approach to detecting changes in cognitive states. Front Psychiatry. 2020;11:12.
doi: 10.3389/fpsyt.2020.00012
Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacology. 2016;41:419–30.
doi: 10.1038/npp.2015.162
Arce E, Balice-Gordon R, Duvvuri S, Naylor M, Xie Z, Harel B, et al. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia. J Psychopharmacol. 2019;33:1237–47.
doi: 10.1177/0269881119855302
Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015;40:446–53.
doi: 10.1038/npp.2014.192
Light GA, Swerdlow NR. Selection criteria for neurophysiologic biomarkers to accelerate the pace of CNS therapeutic development. Neuropsychopharmacology. 2020;45:237–8.
doi: 10.1038/s41386-019-0519-0
Light GA, Joshi YB, Molina JL, Bhakta SG, Nungaray JA, Cardoso L, et al. Neurophysiological biomarkers for schizophrenia therapeutics. Biomark Neuropsychiatry. 2020;2. https://doi.org/10.1016/j.bionps.2020.100012 .
Joshi YB, Tarasenko M, Light GA. Applications of neurophysiological biomarkers in CNS drug development: focus on psychoses. Handb Behav Neurosci. 2019;29:191–8.
doi: 10.1016/B978-0-12-803161-2.00012-6
Sahin M, Jones SR, Sweeney JA, Berry-Kravis E, Connors BW, Ewen JB, et al. Discovering translational biomarkers in neurodevelopmental disorders. Nat Rev Drug Discov. 2018. https://doi.org/10.1038/d41573-018-00010-7 .
Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, et al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PloS ONE. 2012;7:e39434.
doi: 10.1371/journal.pone.0039434
Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, et al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiatry. 2017;74:37–46.
doi: 10.1001/jamapsychiatry.2016.2980
Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62:127–36.
doi: 10.1001/archpsyc.62.2.127
Light GA, Braff DL. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005;162:1741–3.
doi: 10.1176/appi.ajp.162.9.1741
Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007;13:653–63.
doi: 10.1017/S1355617707070816
Kiang M, Kutas M, Light GA, Braff DL. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007;92:225–36.
doi: 10.1016/j.schres.2007.02.001
Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, et al. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012;123:1942–9.
doi: 10.1016/j.clinph.2012.02.079
Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, et al. Mismatch negativity is a sensitive and predictive biomarker of perceptual learning during auditory cognitive training in schizophrenia. Neuropsychopharmacology. 2017;42:2206–13.
doi: 10.1038/npp.2017.25
Perez VB, Miyakoshi M, Makeig SD, Light GA. Mismatch negativity reveals plasticity in cortical dynamics after 1-hour of auditory training exercises. Int J Psychophysiol. 2019;145:40–7.
doi: 10.1016/j.ijpsycho.2019.06.003
Hochberger WC, Thomas ML, Joshi YB, Molina J, Treichler EBH, Nungaray J, et al. Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. Schizophr Res. 2020;215:97–104.
doi: 10.1016/j.schres.2019.11.015
Hochberger WC, Joshi YB, Thomas ML, Zhang W, Bismark AW, Treichler EBH, et al. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology. 2019;44:606–12.
doi: 10.1038/s41386-018-0256-9